Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 210

1.

Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial.

Filippatos G, Farmakis D, Colet JC, Dickstein K, Lüscher TF, Willenheimer R, Parissis J, Gaudesius G, Mori C, von Eisenhart Rothe B, Greenlaw N, Ford I, Ponikowski P, Anker SD.

Eur J Heart Fail. 2013 Nov;15(11):1267-76. doi: 10.1093/eurjhf/hft099. Epub 2013 Jun 19.

2.

The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study.

Comin-Colet J, Lainscak M, Dickstein K, Filippatos GS, Johnson P, Lüscher TF, Mori C, Willenheimer R, Ponikowski P, Anker SD.

Eur Heart J. 2013 Jan;34(1):30-8. doi: 10.1093/eurheartj/ehr504. Epub 2012 Jan 31.

3.

Ferric carboxymaltose in patients with heart failure and iron deficiency.

Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P; FAIR-HF Trial Investigators.

N Engl J Med. 2009 Dec 17;361(25):2436-48. doi: 10.1056/NEJMoa0908355. Epub 2009 Nov 17.

4.

Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia.

Anker SD, Colet JC, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Mori C, von Eisenhart Rothe B, Pocock S, Poole-Wilson PA, Ponikowski P; FAIR-HF committees and investigators.

Eur J Heart Fail. 2009 Nov;11(11):1084-91. doi: 10.1093/eurjhf/hfp140.

5.

The effect of intravenous ferric carboxymaltose on red cell distribution width: a subanalysis of the FAIR-HF study.

Van Craenenbroeck EM, Conraads VM, Greenlaw N, Gaudesius G, Mori C, Ponikowski P, Anker SD.

Eur J Heart Fail. 2013 Jul;15(7):756-62. doi: 10.1093/eurjhf/hft068. Epub 2013 May 2.

6.

Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†.

Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD; CONFIRM-HF Investigators.

Eur Heart J. 2015 Mar 14;36(11):657-68. doi: 10.1093/eurheartj/ehu385. Epub 2014 Aug 31.

7.

The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study.

Ponikowski P, Filippatos G, Colet JC, Willenheimer R, Dickstein K, Lüscher T, Gaudesius G, von Eisenhart Rothe B, Mori C, Greenlaw N, Ford I, Macdougall I, Anker SD; FAIR-HF Trial Investigators.

Eur J Heart Fail. 2015 Mar;17(3):329-39. doi: 10.1002/ejhf.229. Epub 2015 Feb 11.

8.

Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.

Lyseng-Williamson KA, Keating GM.

Drugs. 2009;69(6):739-56. doi: 10.2165/00003495-200969060-00007. Review.

PMID:
19405553
9.

Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis.

Gutzwiller FS, Pfeil AM, Comin-Colet J, Ponikowski P, Filippatos G, Mori C, Braunhofer PG, Szucs TD, Schwenkglenks M, Anker SD.

Int J Cardiol. 2013 Oct 9;168(4):3878-83. doi: 10.1016/j.ijcard.2013.06.045. Epub 2013 Jul 17.

10.

[Anaemia and iron deficiency in clinical practice:from cardiology to gastroenterology and beyond].

Češka R.

Vnitr Lek. 2014 Dec;60(12):1033-9. Review. Czech.

PMID:
25692829
11.

TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.

Schatz U, Illigens BM, Siepmann T, Arneth B, Siegert G, Siegels D, Heigl F, Hettich R, Ramlow W, Prophet H, Bornstein SR, Julius U.

Atheroscler Suppl. 2015 May;18:199-208. doi: 10.1016/j.atherosclerosissup.2015.02.030.

PMID:
25936327
12.

Relation of Longitudinal Changes in Quality of Life Assessments to Changes in Functional Capacity in Patients With Heart Failure With and Without Anemia.

Cooper TJ, Anker SD, Comin-Colet J, Filippatos G, Lainscak M, Lüscher TF, Mori C, Johnson P, Ponikowski P, Dickstein K.

Am J Cardiol. 2016 May 1;117(9):1482-7. doi: 10.1016/j.amjcard.2016.02.018. Epub 2016 Feb 17.

PMID:
27015889
13.

Cost-effectiveness analysis of ferric carboxymaltose in iron-deficient patients with chronic heart failure in Sweden.

Hofmarcher T, Borg S.

J Med Econ. 2015;18(7):492-501. doi: 10.3111/13696998.2015.1029491. Epub 2015 Mar 31.

PMID:
25766863
14.

Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UK.

Gutzwiller FS, Schwenkglenks M, Blank PR, Braunhofer PG, Mori C, Szucs TD, Ponikowski P, Anker SD.

Eur J Heart Fail. 2012 Jul;14(7):782-90. doi: 10.1093/eurjhf/hfs083. Epub 2012 Jun 11.

15.

The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study.

Covic A, Mircescu G.

Nephrol Dial Transplant. 2010 Aug;25(8):2722-30. doi: 10.1093/ndt/gfq069. Epub 2010 Feb 26.

16.

Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.

Geisser P, Banké-Bochita J.

Arzneimittelforschung. 2010;60(6a):362-72. doi: 10.1055/s-0031-1296301.

PMID:
20648928
17.
18.

Ferric carboxymaltose: a review of its use in iron deficiency.

Keating GM.

Drugs. 2015 Jan;75(1):101-27. doi: 10.1007/s40265-014-0332-3. Review.

PMID:
25428711
19.

Clinical use of ferric carboxymaltose in patients with solid tumours or haematological malignancies in France.

Toledano A, Luporsi E, Morere JF, Scotté F, Laribi K, Barrière J, Huot-Marchand P, Duvillié L, Concas VH, Bugat R.

Support Care Cancer. 2016 Jan;24(1):67-75. doi: 10.1007/s00520-015-2728-3. Epub 2015 Apr 29.

PMID:
25921449
20.

A Cost-effectiveness Analysis of Ferric Carboxymaltose in Patients With Iron Deficiency and Chronic Heart Failure in Spain.

Comín-Colet J, Rubio-Rodríguez D, Rubio-Terrés C, Enjuanes-Grau C, Gutzwiller FS, Anker SD, Ponikowski P.

Rev Esp Cardiol (Engl Ed). 2015 Oct;68(10):846-51. doi: 10.1016/j.rec.2014.10.010. Epub 2015 Jan 28.

PMID:
25649970

Supplemental Content

Support Center